COXITAS-Etoricoxib 60, 90, 120 mg Tablet COXITAS P- Etoricoxib 60mg + Paracetamol 325 mg Tablet COXITAS TH- Etoricoxib 60mg + Thiocolchicoside 4mg Tablet
COXITAS-Etoricoxib 60, 90, 120 mg Tablet COXITAS P- Etoricoxib 60mg + Paracetamol 325 mg Tablet COXITAS TH- Etoricoxib 60mg + Thiocolchicoside 4mg Tablet
Acute and chronic treatment of the signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA)
• Treatment of ankylosing spondylitis (AS)
• Treatment of acute gouty arthritis
• Treatment of acute pain, including that related to primary dysmenorrhoea and minor dental procedures. The decision to prescribe a selective COX-2 inhibitor should be based on an assessment of the individual patient’s overall risks.
How it works
Etoricoxib is a nonsteroidal anti-inflammatory agent (dipyridinyl derivative) for oral administration. It is a highly selective inhibitor of cyclooxygenase-2 (COX-2) that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. The inducible COX-2 isoform is expressed at sites of inflammation, and its inhibition is considered responsible for analgesic and anti-inflammatory properties of nonsteroidal anti-inflammatory agents.
Paracetamol belongs to a group of medicines known as analgesics, or painkillers. It is used to relieve mild to moderate pain.
Thiocolchicoside is a muscle relaxant with anti-inflammatory and analgesic effects. It acts as a competitive GABAA receptor antagonist and also glycine receptor antagonist with similar potency and nicotinic acetylcholine receptors to a much lesser extent.
Indications
Acute and chronic treatment of the signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA)
• Treatment of ankylosing spondylitis (AS)
• Treatment of acute gouty arthritis
• Treatment of acute pain, including that related to primary dysmenorrhoea and minor dental procedures. The decision to prescribe a selective COX-2 inhibitor should be based on an assessment of the individual patient’s overall risks.
Dosage
• Osteoarthritis:The recommended dose of etoricoxib is 30 mg or 60 mg once daily.
• Rheumatoid Arthritis:The recommended dose of etoricoxib is 90 mg once daily.
• Ankylosing Spondylitis:The recommended dose of etoricoxib is 90 mg once daily.
• Acute Gouty Arthritis:The recommended dose of etoricoxib is 120 mg once daily. Etoricoxib 120 mg should be used only for the acute symptomatic period, limited to a maximum of 8 days treatment. Analgesia
• Acute Pain and Primary Dysmenorrhea:The recommended dose is 120 mg once daily. Etoricoxib 120 mg should be used only for the acute symptomatic period, limited to a maximum of 8 days treatment. Doses greater than those recommended for each indication have either not demonstrated additional efficacy or have not been studied.
• The dose for OA should not exceed 60 mg daily.
• The dose for RA should not exceed 90 mg daily.
• The dose for ankylosing spondylitis should not exceed 90 mg daily.
• The dose for acute gout should not exceed 120 mg daily.
• The dose for acute pain and primary dysmenorrhea should not exceed 120 mg daily.
As the cardiovascular risks of selective COX-2 inhibitors may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. The patient’s need for symptomatic relief and response to therapy should be re-evaluated periodically.
Side Effects
• Blood and lymphatic system disorders: thrombocytopenia
• Immune system disorders: hypersensitivity reactions, anaphylactic/anaphylactoid reactions including shock
• Metabolism and nutrition disorders: hyperkalemia
• Psychiatric disorders: anxiety, insomnia, confusion, hallucinations, depression, restlessness
• Nervous system disorders: dysgeusia, somnolence
• Eye disorders: blurred vision
• Cardiac disorders: congestive heart failure, palpitations, angina, arrhythmia Vascular disorders: hypertensive crisis
Contraindication
• Hypersensitivity to any component of this product.
• Congestive heart failure
• Established ischemic heart disease, peripheral arterial disease and/or cerebrovascular disease (including patients who have recently undergone coronary artery bypass graft surgery or angioplasty)
• Pregnancy
• Patients with hypertension whose blood pressure has not been adequately controlled
• Renal impairment associated with a creatinine clearance of less than 30 mL/minute
Copyright © 2020 tasmed
.png)
